BioNTech WKN: A2PSR2 ISIN: US09075V1026 Kürzel: 22UA Forum: Aktien Thema: Hauptdiskussion

Ich hatte da längere Zeit nicht mehr reingeschaut, aber in Kununu sind ja im September tatsächlich neue Highlights eingestellt worden. Es ist wie immer mit Bewertungen im Internet: Mit Vorsicht zu genießen. Aber wenn nahezu alle Bewertenden mehr oder weniger das gleiche schreiben, wird man das schon ernst nehmen müssen. Fazit dort: Die Leute sitzen tatsächlich vielfach nur ihre Zeit ab ohne sinnvolle Aufgabe und mangels Kommunikation weiß keiner, ob und ggf wie es weiterheht. Ein führungsloses Geisterschiff. Das dürfte in der Form einzigartig sein in der deutschen Unternehmenslandschaft.

Wall Street Analysts Are Bullish on Top Healthcare Picks TipRanks Newsroom Sep 16, 2026, 08:50 AM UBS analyst David Dai maintained a Buy rating on BioNTech SE today and set a price target of $135.00. The company’s shares closed last Tuesday at $96.69. According to TipRanks.com, Dai is a 4-star analyst with an average return of 15.8% and a 64.2% success rate. Dai covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Syndax Pharmaceuticals, and Telix Pharmaceuticals. https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-340?mod=mw_quote_news

BioNTech ADRs Gain on Positive Data From Lung Cancer Trial Sept. 14, 2026, 12:56 p.m. ET By Elias Schisgall American depositary receipts of BioNTech were higher after the company said gotistobart, a lung cancer treatment, nearly doubled median survival in a Phase 3 trial. The biotechnology company on Monday said gotistobart, developed in collaboration with OncoC4, demonstrated a median overall survival of 18.5 months in patients with squamous non-small lung cancer whose disease had progressed in prior treatments. That compares with a median overall survival of 10 months for standard-of-care chemotherapy, the company said. "The magnitude of the survival benefit observed with gotistobart as a chemotherapy-free treatment approach in the PRESERVE-003 clinical trial is highly encouraging," said the study's principal investigator, Rama Balaraman. "If confirmed in the pivotal portion of the Phase 3 trial, these findings could transform the standard of care in a setting where new therapies are urgently needed." The data came from the first stage of the Phase 3 trial. The second stage is ongoing at upwards of 160 sites globally, BioNTech said. https://www.marketwatch.com/story/biontech-adrs-gain-on-positive-data-from-lung-cancer-trial-1f887327?mod=mw_quote_news

Außer sie startet durch.👍😁

Die letzten News waren gut. Also abwarten. Habe wieder eine kleine Position aufgebaut. Richtung 100€ verkaufe ich dann wieder.😉

Morgan Stanley. Mein Lieblingsbroker: BioNTech SE (BNTX) Gets a Buy from Morgan Stanley TipRanks Auto-Generated Intelligence Newsdesk Sep 14, 2026, 11:55 AM BioNTech SE (BNTX) Gets a Buy from Morgan Stanley In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE, with a price target of $115.00. Flynn covers the Healthcare sector, focusing on stocks such as BioNTech SE, Moderna, and Biogen. According to TipRanks, Flynn has an average return of 9.5% and a 59.19% success rate on recommended stocks.

Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL) and BioNTech SE (BNTX) TipRanks Newsroom Sep 15, 2026, 02:40 PM BioNTech SE (BNTX) In a report released yesterday, Evan Seigerman from BMO Capital maintained a Hold rating on BioNTech SE, with a price target of $105.00. The company’s shares closed last Tuesday at $96.20. According to TipRanks.com, Seigerman is a 5-star analyst with an average return of 9.9% and a 58.1% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Protagonist Therapeutics, and Vertex Pharmaceuticals. Currently, the analyst consensus on BioNTech SE is a Strong Buy with an average price target of $126.23. https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ocular-therapeutix-ocul-and-biontech-se-bntx-blurbs-news?mod=mw_quote_news

BioNTech: Buy Rating Reiterated on Strengthening Oncology Pipeline and De-Risked Programs; Price Target Unchanged at $127 TipRanks Auto-Generated Intelligence Newsdesk Sep 15, 2026, 01:35 PM BioNTech: Buy Rating Reiterated on Strengthening Oncology Pipeline and De-Risked Programs; Price Target Unchanged at $127 Goldman Sachs analyst Asad Haider has maintained their bullish stance on BNTX stock, giving a Buy rating today. Asad Haider has given his Buy rating due to a combination of factors tied to BioNTech’s strengthening oncology pipeline and de-risked clinical programs. The latest overall survival data for gotistobart in second-line and later squamous non-small cell lung cancer show a substantial survival advantage versus chemotherapy, which Haider views as confirming a compelling efficacy profile and reducing execution risk ahead of the pivotal stage 2 readout in late 2026. Haider also highlights a series of upcoming data catalysts across BioNTech’s novel combinations and mRNA cancer immunotherapies, which could further validate its strategy and support long-term growth. In addition, positive read-across from external programs, particularly for pumitamig, reinforces confidence in BioNTech’s key assets and supports his unchanged price target of $127, implying meaningful upside potential from current levels. https://www.tipranks.com/news/ratings/biontech-buy-rating-reiterated-on-strengthening-oncology-pipeline-and-de-risked-programs-price-target-unchanged-at-127-ratings-news?mod=mw_quote_news

Jefferies & Company Inc. BioNTech (ADRs) Buy 08:56 Uhr NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Biontech auf "Buy" mit einem Kursziel von 138 US-Dollar belassen. Die Mainzer hätten auf dem Welt-Lungenkrebskongress erstmals Daten aus einer "Novel-Novel"-Kombinationstherapie präsentiert, schrieb Akash Tewari in seinem am Mittwoch vorliegenden Kommentar. Damit bezeichnet man den gemeinsamen Einsatz von zwei oder mehr neuartiger Wirkstoffe. Im konkreten Fall hätten Pumitamig und Elfetabart starke frühe Wirksamkeitssignale (Early Efficacy Signals) bei kleinzelligem Lungenkarzinom gezeigt - bei ebenfalls ermutigender Verträglichkeit./ag/tih Veröffentlichung der Original-Studie: 15.09.2026 / 23:47 / ET Erstmalige Weitergabe der Original-Studie: 15.09.2026 / 23:47 / ET

Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) BioNTech (ADRs) Buy 08:41 Uhr HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Biontech von 132 auf 140 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Analyst Harry Gillis honoriert damit starke Ergebnisse in Lungenkrebs-Studien, wie er am Dienstag schrieb. Pumitamig und Elfetabart sähen gegen kleinzellige Lungenkarzinome in Kombination sehr gut aus./rob/ag/jha/ Veröffentlichung der Original-Studie: 15.09.2026 / 16:40 / GMT

Jefferies & Company Inc. BioNTech (ADRs) Buy 15.09.26 NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat Biontech auf "Buy" mit einem Kursziel von 138 US-Dollar belassen. Biontechs Immuntherapie-Wirkstoff Gotistobart habe in einer klinischen Studie zur Bekämpfung einer bestimmten Form von Lungenkrebs gut abgeschnitten, lobte Akash Tewari in einer am Dienstag vorliegenden Einschätzung./rob/gl/la Veröffentlichung der Original-Studie: 15.09.2026 / 10:21 / Zeitzone in Studie nicht angegeben Erstmalige Weitergabe der Original-Studie: 15.09.2026 / 10:21

Berenberg Bank Reaffirms Their Buy Rating on BioNTech SE (BNTX) TipRanks Auto-Generated Intelligence Newsdesk Sep 16, 2026, 05:35 AM Berenberg Bank Reaffirms Their Buy Rating on BioNTech SE (BNTX) In a report released yesterday, Harry Gillis from Berenberg Bank maintained a Buy rating on BioNTech SE, with a price target of $140.00. The company’s shares closed yesterday at $96.69. According to TipRanks, Gillis is a 4-star analyst with an average return of 20.9% and a 68.85% success rate. Gillis covers the Healthcare sector, focusing on stocks such as Qiagen, Tecan Group AG, and Moderna. Currently, the analyst consensus on BioNTech SE is a Strong Buy with an average price target of $126.85, a 31.19% upside from current levels. In a report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $136.00 price target.https://www.tipranks.com/news/blurbs/berenberg-bank-reaffirms-their-buy-rating-on-biontech-se-bntx-blurbs-news?mod=mw_quote_news

Den Anstieg hätte man direkt mitnehmen müssen 😉

Ist nicht ganz korrekt. Der Anstieg lag an einem vermeintlichen Erfolg mit Krebsimpfstoffen bei Moderna. Davon profitiert Biontech dann natürlich auch. Wäre umgekehrt genauso.

Der Anstieg vor 3 Wochen hatte ja rein gar nichts mit Biontech zu tun und war nur aufgrund von Moderna. Aber hier glaubt man ja ................